Dipeptidyl peptidase IV inhibitors: A new class of oral agents for treatment of type 2 diabetes mellitus
- Author:
Le CAI
1
Author Information
1. Department of TCMM of Pharmaceutical Care Center
- Publication Type:Journal Article
- Keywords:
Antidiabetes drugs;
Diabetes mellitus;
Dipeptidyl peptidase IV inhibitors;
Glucagon-like peptide 1
- From:
Journal of International Pharmaceutical Research
2010;37(5):361-365
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 (GLP-1), one kind of incretins, contributes to control blood glucose level with several routines. It can be degraded rapidly by the enzyme dipeptidyl peptidase IV (DPP-IV). DPP-IV inhibitors augment glucose homeostasis by preventing degradation of GLP-1, which can stimulate insulin secretion, inhibit glucagon secretion, increase satiety, and slow gastric emptying. They are weight neutral, and are associated with low risk of hypoglycemia. This review highlights the characteristics of GLP-1, clinical efficacy, pharmacokinetics and adverse reactions of DPP-IV inhibitors.
